Nieva also discussed the ROS1 fusion partner subgroup. Whether the partner was CD74 or another gene, the overall response ...
Fast track designation targets a post–immunotherapy and post-platinum KRAS G12C–mutant NSCLC population, enabling closer FDA ...
The Journal of Targeted Therapies in Cancer | Targeted Publications | Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results